<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="901">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04456452</url>
  </required_header>
  <id_info>
    <org_study_id>AP-016</org_study_id>
    <nct_id>NCT04456452</nct_id>
  </id_info>
  <brief_title>Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation</brief_title>
  <official_title>A Randomized Controlled Trial to Evaluate the Safety of Intravenous Ampionâ„¢ in Adult COVID-19 Patients Requiring Oxygen Supplementation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ampio Pharmaceuticals. Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ampio Pharmaceuticals. Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 randomized study to evaluate the safety, tolerability and efficacy of IV
      Ampion in improving the clinical course and outcomes of patients hospitalized with COVID-19
      infection who require supplemental oxygen.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 27, 2020</start_date>
  <completion_date type="Anticipated">November 13, 2020</completion_date>
  <primary_completion_date type="Actual">September 8, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events</measure>
    <time_frame>Primary endpoint at day 5</time_frame>
    <description>Incidence and severity of adverse events</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Ampion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ampion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard of Care</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ampion</intervention_name>
    <description>Ampion, administered by intravenous infusion</description>
    <arm_group_label>Ampion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Standard of Care</description>
    <arm_group_label>Ampion</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, 18 years to 89 years old (inclusive).

          2. Hospitalized and diagnosed with COVID-19, as evaluated by PCR test confirming
             infection with SARS-COV-2.

          3. Patient is receiving supplemental oxygen (e.g. oxygen saturation (SpO2) &lt;88%, labored
             breathing, increased respiratory rate, dyspnea on rest or exertion).

          4. A signed informed consent form from the patient or the patient's legal representative
             must be available.

        Exclusion Criteria:

          1. In the opinion of the clinical team, progression to death is imminent and inevitable,
             irrespective of the provision of treatments.

          2. Patient has severe chronic obstructive pulmonary disease (COPD), chronic renal
             failure, or significant liver abnormality (e.g. cirrhosis, transplant, etc.).

          3. Patient is on chronic immunosuppressive medication.

          4. As a result of the medical review and screening investigation, the Principal
             Investigator considers the patient unfit for the study.

          5. A history of allergic reactions to human albumin (reaction to non-human albumin such
             as egg albumin is not an exclusion criterion) or excipients in 5% human albumin
             (N-acetyltryptophan, sodium caprylate).

          6. Patient has known pregnancy or is currently breastfeeding.

          7. Participation in another clinical trial.

          8. Baseline QT prolongation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 30, 2020</study_first_submitted>
  <study_first_submitted_qc>June 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2020</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

